Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (52-week) improvement in measures of disease activity in patients with psoriatic arthritis: Results from 3 phase 3, randomized, controlled trials
Services
Services
Date issued
2014Journal title
Arthritis and Rheumatology
Type of content
Publicación de congreso
